Literature DB >> 2843137

Failure of intraventricular gammaglobulin and alpha interferon for persistent encephalitis in congenital hypogammaglobulinaemia.

D M Roberton1, I Jack, W Joshi, F Law, C S Hosking.   

Abstract

A boy with congenital hypogammaglobulinaemia died at the age of 12 years after a viral meningoencephalitis of two and a half years duration due to an untypable picornavirus. He had received intravenous immunoglobulin every four weeks from the time of the start of immunoglobulin replacement treatment at the age of 3 years. The encephalitis did not respond to high dose intravenous gammaglobulin (2500 g during 22 months). The virus could not be isolated during the administration of intraventricular immunoglobulin (38.15 g) and intraventricular recombinant alpha interferon (121 X 10(6) units), but recurred rapidly each time intraventricular treatment was stopped. Further modes of treatment are still required for prevention and treatment of this disorder.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2843137      PMCID: PMC1778993          DOI: 10.1136/adc.63.8.948

Source DB:  PubMed          Journal:  Arch Dis Child        ISSN: 0003-9888            Impact factor:   3.791


  20 in total

1.  Poliomyelitis in hypogammaglobulinemics.

Authors:  H V Wyatt
Journal:  J Infect Dis       Date:  1973-12       Impact factor: 5.226

2.  Persistent and fatal central-nervous-system ECHOvirus infections in patients with agammaglobulinemia.

Authors:  C M Wilfert; R H Buckley; T Mohanakumar; J F Griffith; S L Katz; J K Whisnant; P A Eggleston; M Moore; E Treadwell; M N Oxman; F S Rosen
Journal:  N Engl J Med       Date:  1977-06-30       Impact factor: 91.245

3.  Fatal ECHO 24 infection in a patient with hypogammaglobulinemia: relationship to dermatomyositis-like syndrome.

Authors:  J A Bardelas; J A Winkelstein; D S Seto; T Tsai; A D Rogol
Journal:  J Pediatr       Date:  1977-03       Impact factor: 4.406

4.  Successful treatment of echovirus meningoencephalitis and myositis-fasciitis with intravenous immune globulin therapy in a patient with X-linked agammaglobulinemia.

Authors:  P J Mease; H D Ochs; R J Wedgwood
Journal:  N Engl J Med       Date:  1981-05-21       Impact factor: 91.245

5.  Effect of specific antibodies on chronic echovirus type 5 encephalitis in a patient with hypogammaglobulinemia.

Authors:  L S Weiner; J T Howell; M P Langford; G J Stanton; S Baron; R M Goldblum; R A Lord; A S Goldman
Journal:  J Infect Dis       Date:  1979-12       Impact factor: 5.226

6.  Inhibition of rhinovirus replication in in organ culture by a potential antiviral drug.

Authors:  D C DeLong; S E Reed
Journal:  J Infect Dis       Date:  1980-01       Impact factor: 5.226

7.  Echovirus encephalitis and myositis in primary immunoglobulin deficiency.

Authors:  A D Webster; J H Tripp; A R Hayward; A D Dayan; R Doshi; E H Macintyre; D A Tyrrell
Journal:  Arch Dis Child       Date:  1978-01       Impact factor: 3.791

8.  Vaccine-associated poliomyelitis in a child with sex-linked agammaglobulinemia.

Authors:  P F Wright; M H Hatch; A G Kasselberg; S P Lowry; W B Wadlington; D T Karzon
Journal:  J Pediatr       Date:  1977-09       Impact factor: 4.406

9.  Central nervous system echovirus infection in Bruton's X-linked hypogammaglobulinemia.

Authors:  R L Prentice; A G Dalgleish; P A Gatenby; R H Loblay; S Wade; N Kappagoda; A Basten
Journal:  Aust N Z J Med       Date:  1985-08

10.  Intrathecal interferon reduces exacerbations of multiple sclerosis.

Authors:  L Jacobs; J O'Malley; A Freeman; R Ekes
Journal:  Science       Date:  1981-11-27       Impact factor: 47.728

View more
  2 in total

1.  Use of intravenous immunoglobulins in drug-resistant epilepsy.

Authors:  A Fois; M Vascotto
Journal:  Childs Nerv Syst       Date:  1990-11       Impact factor: 1.475

Review 2.  Chronic enteroviral meningoencephalitis in agammaglobulinemia: case report and literature review.

Authors:  S A Misbah; G P Spickett; P C Ryba; J M Hockaday; J S Kroll; C Sherwood; J B Kurtz; E R Moxon; H M Chapel
Journal:  J Clin Immunol       Date:  1992-07       Impact factor: 8.317

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.